Paper37484262
Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines.
Gugu TH and 9 others. Heliyon, 2023. Cited by 3 papers, by iCite. Retracted.
Cite this record
ConductScience Library. Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines. Papers, record 37484262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37484262
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Retracted by | 38618648 | Retraction notice to "Mechanistic insight into the bioactivity of prodigiosin-entrapped lipid nanoparticles against triple-negative breast, lung and colon cancer cell lines" [Heliyon 9 (2023) e16963]. | https://conductscience.org/library/papers/38618648 |
Source PubMed
References43
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30400387 | Biological Potential and Mechanism of Prodigiosin from Serratia marcescens Subsp. lawsoniana in Human Choriocarcinoma and Prostate Cancer Cell Lines. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30400387 | PubMed |
| 2 | 22929442 | Drug transport across the blood-brain barrier. | J Cereb Blood Flow Metab | 2012 | https://conductscience.org/library/papers/22929442 | PubMed |
| 3 | 24583638 | Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. | Cell Death Differ | 2014 | https://conductscience.org/library/papers/24583638 | PubMed |
| 4 | 36577970 | Rise of the natural red pigment 'prodigiosin' as an immunomodulator in cancer. | Cancer Cell Int | 2022 | https://conductscience.org/library/papers/36577970 | PubMed |
| 5 | 27573798 | Spiro[pyrrolidine-3, 3´-oxindole] as potent anti-breast cancer compounds: Their design, synthesis, biological evaluation and cellular target identification. | Sci Rep | 2016 | https://conductscience.org/library/papers/27573798 | PubMed |
| 6 | 30065243 | Systems analysis of intracellular pH vulnerabilities for cancer therapy. | Nat Commun | 2018 | https://conductscience.org/library/papers/30065243 | PubMed |
| 7 | 11828428 | Synthesis and biological evaluation of nonylprodigiosin and macrocyclic prodigiosin analogues. | Chembiochem | 2001 | https://conductscience.org/library/papers/11828428 | PubMed |
| 8 | 17406391 | Sulforhodamine B colorimetric assay for cytotoxicity screening. | Nat Protoc | 2006 | https://conductscience.org/library/papers/17406391 | PubMed |
| 9 | 11015311 | Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer cell lines. | Br J Pharmacol | 2000 | https://conductscience.org/library/papers/11015311 | PubMed |
| 10 | 24247721 | Prodigiosin rescues deficient p53 signaling and antitumor effects via upregulating p73 and disrupting its interaction with mutant p53. | Cancer Res | 2014 | https://conductscience.org/library/papers/24247721 | PubMed |
| 11 | 30042582 | Antioxidant and antimicrobial activity of bioactive prodigiosin produces from Serratia marcescens using agricultural waste as a substrate. | J Food Sci Technol | 2018 | https://conductscience.org/library/papers/30042582 | PubMed |
| 12 | 35163625 | Disruption of Kidney-Immune System Crosstalk in Sepsis with Acute Kidney Injury: Lessons Learned from Animal Models and Their Application to Human Health. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163625 | PubMed |
| 13 | 26652344 | Swelling of poly(N-isopropylacrylamide) P(NIPA)-based hydrogels with bacterial-synthesized prodigiosin for localized cancer drug delivery. | Mater Sci Eng C Mater Biol Appl | 2016 | https://conductscience.org/library/papers/26652344 | PubMed |
| 14 | 26344956 | Prodigiosin and its potential applications. | J Food Sci Technol | 2015 | https://conductscience.org/library/papers/26344956 | PubMed |
| 15 | 16126233 | Non-apoptotic concentrations of prodigiosin (H+/Cl- symporter) inhibit the acidification of lysosomes and induce cell cycle blockage in colon cancer cells. | Life Sci | 2005 | https://conductscience.org/library/papers/16126233 | PubMed |
| 16 | 34967848 | Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. | JAMA Oncol | 2022 | https://conductscience.org/library/papers/34967848 | PubMed |
| 17 | 9705273 | Prodigiosins as a new group of H+/Cl- symporters that uncouple proton translocators. | J Biol Chem | 1998 | https://conductscience.org/library/papers/9705273 | PubMed |
| 18 | 11036689 | The natural functions of secondary metabolites. | Adv Biochem Eng Biotechnol | 2000 | https://conductscience.org/library/papers/11036689 | PubMed |
| 19 | 27799526 | Prodigiosin inhibits Wnt/β-catenin signaling and exerts anticancer activity in breast cancer cells. | Proc Natl Acad Sci U S A | 2016 | https://conductscience.org/library/papers/27799526 | PubMed |
| 20 | 17671126 | Triple-negative breast cancer: clinical features and patterns of recurrence. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17671126 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38794306 | Lipid Nanoparticles in Lung Cancer Therapy. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38794306 | PubMed |
| 38275722 | The Golgi Apparatus as an Anticancer Therapeutic Target. | Biology (Basel) | 2023 | https://conductscience.org/library/papers/38275722 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATR | 545 | PubTator's text mining | https://conductscience.org/library/genes/545 | NCBI Gene |
| CTNNB1 | 1499 | PubTator's text mining | https://conductscience.org/library/genes/1499 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| PNP | 4860 | PubTator's text mining | https://conductscience.org/library/genes/4860 | NCBI Gene |
| SFTPC | 6440 | PubTator's text mining | https://conductscience.org/library/genes/6440 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37484262
GET https://conductscience.org/api/papers/v1/37484262/references?page=2